February 2013 FDA Recall Drug by Sanofi-synthelabo
D-886-2013 - Subpotent Drug
This Class II drug recall was voluntarily initiated by Sanofi-synthelabo on February 26, 2013 for the product Drug. The FDA reported the reason for recall as subpotent drug. The product was distributed in Canada and the recall is currently terminated.
Recall Number: D-886-2013
Subpotent Drug: During review of retain samples, the manufacturer observed low fill in some capsules, which was related to an issue detected with the encapsulating equipment.
02-26-2013
08-21-2013
998 Bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Sanofi-Synthelabo
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
Canada
06-06-2014
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Rifadin (rifampin) capsules, USP, 150 mg, 100-count capsules per bottle, Manufactured by: Fabrique par Sanofi-Aventis Canada Inc., Laval, Quebec, Canada H7L4A8, DIN # 02091887
Batch or Lot Expiration Information
Lot# 3099036, Exp 03/2014